Quick Answer
Aptevo Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $21.62 million for the year ending 2025.
- Aptevo Therapeutics Inc. showed an increase of +148.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Aptevo Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 501.7%.
- Historical annual values: Fiscal year 2025: $21.62 million | Fiscal year 2024: $8.71 million | Fiscal year 2023: $16.90 million | Fiscal year 2022: $22.64 million | Fiscal year 2021: $45.04 million | Fiscal year 2020: $39.98 million | Fiscal year 2019: $12.45 million | Fiscal year 2018: $30.64 million | Fiscal year 2017: $7.10 million | Fiscal year 2016: $9.68 million | Fiscal year 2015: $4.64 million | Fiscal year 2014: $3.59 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: